JP2005505539A5 - - Google Patents

Download PDF

Info

Publication number
JP2005505539A5
JP2005505539A5 JP2003522575A JP2003522575A JP2005505539A5 JP 2005505539 A5 JP2005505539 A5 JP 2005505539A5 JP 2003522575 A JP2003522575 A JP 2003522575A JP 2003522575 A JP2003522575 A JP 2003522575A JP 2005505539 A5 JP2005505539 A5 JP 2005505539A5
Authority
JP
Japan
Prior art keywords
methyl
azetidine
chlorophenyl
methylene
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2003522575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005505539A (ja
Filing date
Publication date
Priority claimed from FR0111201A external-priority patent/FR2829027A1/fr
Application filed filed Critical
Publication of JP2005505539A publication Critical patent/JP2005505539A/ja
Publication of JP2005505539A5 publication Critical patent/JP2005505539A5/ja
Abandoned legal-status Critical Current

Links

JP2003522575A 2001-08-29 2002-08-28 パーキンソン病の治療のためのcb1受容体アンタゴニストと、脳のドーパミン作用性神経伝達を活性化する製品を含む組成物 Abandoned JP2005505539A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0111201A FR2829027A1 (fr) 2001-08-29 2001-08-29 Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
PCT/FR2002/002945 WO2003018060A1 (fr) 2001-08-29 2002-08-28 Composition pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau

Publications (2)

Publication Number Publication Date
JP2005505539A JP2005505539A (ja) 2005-02-24
JP2005505539A5 true JP2005505539A5 (OSRAM) 2006-01-05

Family

ID=8866793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003522575A Abandoned JP2005505539A (ja) 2001-08-29 2002-08-28 パーキンソン病の治療のためのcb1受容体アンタゴニストと、脳のドーパミン作用性神経伝達を活性化する製品を含む組成物

Country Status (9)

Country Link
US (1) US7105504B2 (OSRAM)
EP (1) EP1423146A1 (OSRAM)
JP (1) JP2005505539A (OSRAM)
AR (1) AR036303A1 (OSRAM)
CA (1) CA2458855A1 (OSRAM)
FR (1) FR2829027A1 (OSRAM)
IL (1) IL160558A0 (OSRAM)
MX (1) MXPA04001848A (OSRAM)
WO (1) WO2003018060A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
UA83230C2 (ru) 2003-06-11 2008-06-25 Мерк Энд Ко., Инк. Замещенные производные 3-алкил- и 3-алкенилазетидинов
EP1498122A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid systems containing azetidine derivatives
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
KR20080027908A (ko) 2005-06-30 2008-03-28 프로시디온 리미티드 Gpcr 효능제
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
CN101636145B (zh) * 2006-05-31 2014-04-23 雅培产品有限公司 长期24小时经肠给予左旋多巴/卡比多巴
AR064735A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
JP2010514832A (ja) 2007-01-04 2010-05-06 プロシディオン・リミテッド ピペリジンgpcrアゴニスト
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
SI2114933T1 (sl) 2007-01-04 2012-01-31 Prosidion Ltd Windrush Court Piperidinski gpcr-agonisti
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177593A1 (en) * 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them

Similar Documents

Publication Publication Date Title
JP2005505539A5 (OSRAM)
JP4221221B2 (ja) Cb1受容体アンタゴニストおよびシブトラミンの組み合わせ、それらからなる医薬組成物、および肥満の治療におけるそれらの使用
US7037944B2 (en) Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US7105504B2 (en) Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease
RU2001110080A (ru) Производные азетидина, способ их получения и содержащие их лекарственные препараты
JP2005505551A5 (OSRAM)
US7217705B2 (en) Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease
JP2006514942A5 (OSRAM)
RU2008115539A (ru) Производные гидразона и их применение
JP2002053555A5 (OSRAM)
JP2011500679A5 (OSRAM)
DE602004018386D1 (de) Verfahren zur herstellung von 4-(2-dipropylaminoethyl)-1,3-dihydro-2h-indol-2-on-hydrochlorid
RU2019111886A (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
RU96121937A (ru) Производные тропан-2-альдоксима в качестве ингибиторов обратного захвата нейротрансмиттеров
TW200803839A (en) Use of a CB1 antagonist for treating side effects and negative symptoms of schizophrenia
JP2003514893A5 (OSRAM)
JP2003516975A5 (OSRAM)
JP2007508395A5 (OSRAM)
JP2007508392A5 (OSRAM)
RU2006120417A (ru) Бета-лактамы для лечения нарушений цнс
RU2019127116A (ru) Новые соединения, используемые в качестве открывателей калиевых каналов
FR2890862A1 (fr) Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.